{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T04:46:21Z","timestamp":1772081181653,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:00:00Z","timestamp":1759622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:00:00Z","timestamp":1759622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-18450-8","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T05:13:43Z","timestamp":1759641223000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Expanded CD16+CD56+Granzyme B+ NK like CD8+ T cells an off target effect of bruton\u2019s tyrosine kinase inhibitors in Waldenstr\u00f6m macroglobulinemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Priyanka","family":"Hastak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chansavath","family":"Phetsouphanh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zong-Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rowena A.","family":"Bull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lok Bahadur","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Klemm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Louie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Mee Ling","family":"Munier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra Carey","family":"Hopp\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Keoshkerian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Beaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Rankin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony D.","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah C.","family":"Sasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,5]]},"reference":[{"key":"18450_CR1","doi-asserted-by":"publisher","first-page":"204062072198958","DOI":"10.1177\/2040620721989586","volume":"12","author":"I Ntanasis-Stathopoulos","year":"2021","unstructured":"Ntanasis-Stathopoulos, I. et al. Current and novel BTK inhibitors in waldenstr\u00f6m\u2019s macroglobulinemia. Ther. Adv. Hematol. 12, 2040620721989586 (2021).","journal-title":"Ther. Adv. Hematol."},{"issue":"6","key":"18450_CR2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","volume":"25","author":"JA Burger","year":"2019","unstructured":"Burger, J. A. Bruton tyrosine kinase inhibitors: present and future. Cancer J. 25 (6), 386\u2013393 (2019).","journal-title":"Cancer J."},{"issue":"1","key":"18450_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40164-022-00315-9","volume":"11","author":"H Wang","year":"2022","unstructured":"Wang, H. et al. Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect. Experimental Hematol. Oncol. 11 (1), 60 (2022).","journal-title":"Experimental Hematol. Oncol."},{"issue":"1","key":"18450_CR4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","volume":"15","author":"A Alu","year":"2022","unstructured":"Alu, A. et al. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: Mechanisms and clinical studies. J. Hematol. Oncol. 15 (1), 138 (2022).","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"18450_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu, J. et al. Second-generation inhibitors of Bruton tyrosine kinase. J. Hematol. Oncol. 9 (1), 80 (2016).","journal-title":"J. Hematol. Oncol."},{"issue":"Supplement 1","key":"18450_CR6","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1182\/blood-2022-169662","volume":"140","author":"CY Cheah","year":"2022","unstructured":"Cheah, C. Y. et al. A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor Bgb-11417 as monotherapy or in combination with zanubrutinib (ZANU) in patients (Pts) with CLL\/SLL: preliminary data. Blood 140 (Supplement 1), 2321\u20132323 (2022).","journal-title":"Blood"},{"key":"18450_CR7","doi-asserted-by":"crossref","unstructured":"Mhibik, M., Wiestner, A. & Sun, C. Harnessing the effects of BTKi on T cells for effective immunotherapy against CLL. Int. J. Mol. Sci., 21(1). (2019).","DOI":"10.3390\/ijms21010068"},{"issue":"4","key":"18450_CR8","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.4049\/jimmunol.1601190","volume":"198","author":"Q Yin","year":"2017","unstructured":"Yin, Q. et al. Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia. J. Immunol. 198 (4), 1740\u20131747 (2017).","journal-title":"J. Immunol."},{"key":"18450_CR9","doi-asserted-by":"publisher","first-page":"637186","DOI":"10.3389\/fonc.2021.637186","volume":"11","author":"MC Puzzolo","year":"2021","unstructured":"Puzzolo, M. C. et al. TH2\/TH1 shift under ibrutinib treatment in chronic lymphocytic leukemia. Front. Oncol. 11, 637186 (2021).","journal-title":"Front. Oncol."},{"issue":"1","key":"18450_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/ajh.26619","volume":"98","author":"B Beaton","year":"2023","unstructured":"Beaton, B. et al. Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses. Am. J. Hematol. 98 (1), 131\u2013139 (2023).","journal-title":"Am. J. Hematol."},{"issue":"5","key":"18450_CR11","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/bloodadvances.2021006917","volume":"6","author":"S Haggenburg","year":"2022","unstructured":"Haggenburg, S. et al. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. Blood Adv. 6 (5), 1537\u20131546 (2022).","journal-title":"Blood Adv."},{"issue":"21","key":"18450_CR12","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1182\/bloodadvances.2021005444","volume":"5","author":"M Gavriatopoulou","year":"2021","unstructured":"Gavriatopoulou, M. et al. Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: A prospective study. Blood Adv. 5 (21), 4398\u20134405 (2021).","journal-title":"Blood Adv."},{"issue":"3","key":"18450_CR13","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/jha2.724","volume":"4","author":"K Rankin","year":"2023","unstructured":"Rankin, K. et al. Immune response to COVID-19 vaccination in patients with Waldenstr\u00f6m macroglobulinaemia who pause their BTKi therapy. eJHaem 4 (3), 728\u2013732 (2023).","journal-title":"eJHaem"},{"issue":"4\u20135","key":"18450_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/14728222.2023.2218615","volume":"27","author":"D Saberi","year":"2023","unstructured":"Saberi, D. et al. Bruton\u2019s tyrosine kinase as a promising therapeutic target for multiple sclerosis. Expert Opin. Ther. Targets. 27 (4\u20135), 347\u2013359 (2023).","journal-title":"Expert Opin. Ther. Targets"},{"issue":"4","key":"18450_CR15","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.4049\/jimmunol.0803548","volume":"183","author":"JJ Zaunders","year":"2009","unstructured":"Zaunders, J. J. et al. High levels of human antigen-specific CD4\u2009+\u2009T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J. Immunol. 183 (4), 2827\u20132836 (2009).","journal-title":"J. Immunol."},{"key":"18450_CR16","doi-asserted-by":"crossref","unstructured":"Phetsouphanh, C. et al. High titre neutralizing antibodies in response to SARS\u2013CoV\u20132 infection require RBD\u2013specific CD4 T cells that include proliferative memory cells. Front. Immunol., 13. (2022).","DOI":"10.3389\/fimmu.2022.1032911"},{"issue":"6","key":"18450_CR17","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1097\/QAD.0000000000002503","volume":"34","author":"J Zaunders","year":"2020","unstructured":"Zaunders, J. et al. Mapping the extent of heterogeneity of human CCR5\u2009+\u2009CD4\u2009+\u2009T cells in peripheral blood and lymph nodes. AIDS 34 (6), 833\u2013848 (2020).","journal-title":"AIDS"},{"issue":"2","key":"18450_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S2055-6640(20)30056-X","volume":"5","author":"J Zaunders","year":"2019","unstructured":"Zaunders, J. et al. Possible clearance of transfusion-acquired nef\/LTR-deleted attenuated HIV-1 infection by an elite controller with CCR5 \u039432 heterozygous and HLA-B57 genotype. J. Virus Eradication. 5 (2), 73\u201383 (2019).","journal-title":"J. Virus Eradication"},{"issue":"4","key":"18450_CR19","doi-asserted-by":"publisher","first-page":"100228","DOI":"10.1016\/j.xcrm.2021.100228","volume":"2","author":"A Abayasingam","year":"2021","unstructured":"Abayasingam, A. et al. Long-term persistence of RBD(+) memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. Cell. Rep. Med. 2 (4), 100228 (2021).","journal-title":"Cell. Rep. Med."},{"key":"18450_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-1-0716-2756-3_2","volume":"2584","author":"J Ulbrich","year":"2023","unstructured":"Ulbrich, J., Lopez-Salmeron, V. & Gerrard, I. BD rhapsody\u2122 Single-Cell analysis system workflow: From sample to multimodal Single-Cell sequencing data. Methods Mol. Biol. 2584, 29\u201356 (2023).","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"18450_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13059-016-0947-7","volume":"17","author":"L Lun","year":"2016","unstructured":"Lun, L., Bach, A. T. K. & Marioni, J. C. Pooling across cells to normalize single-cell RNA sequencing data with many zero counts. Genome Biol. 17 (1), 75 (2016).","journal-title":"Genome Biol."},{"issue":"7","key":"18450_CR22","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of Single-Cell data. Cell 177 (7), 1888 (2019). \u20131902.e21.","journal-title":"Cell"},{"issue":"1","key":"18450_CR23","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1038\/s41467-021-25960-2","volume":"12","author":"JW Squair","year":"2021","unstructured":"Squair, J. W. et al. Confronting false discoveries in single-cell differential expression. Nat. Commun. 12 (1), 5692 (2021).","journal-title":"Nat. Commun."},{"issue":"6","key":"18450_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell. Syst. 1 (6), 417\u2013425 (2015).","journal-title":"Cell. Syst."},{"key":"18450_CR25","unstructured":"Korotkevich, G. et al. Fast gene set enrichment analysis. bioRxiv, : p. 060012. (2021)."},{"issue":"24","key":"18450_CR26","doi-asserted-by":"publisher","first-page":"11906","DOI":"10.1073\/pnas.1818488116","volume":"116","author":"G Pizzolato","year":"2019","unstructured":"Pizzolato, G. et al. Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRV\u03b41 and TCRV\u03b42 \u03b3\u03b4 T lymphocytes. Proc. Natl. Acad. Sci. U S A. 116 (24), 11906\u201311915 (2019).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"6","key":"18450_CR27","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1182\/bloodadvances.2021006574","volume":"6","author":"C Pleyer","year":"2022","unstructured":"Pleyer, C. et al. BTK inhibitors impair humoral and cellular responses to Recombinant Zoster vaccine in CLL. Blood Adv. 6 (6), 1732\u20131740 (2022).","journal-title":"Blood Adv."},{"issue":"Supplement 1","key":"18450_CR28","doi-asserted-by":"publisher","first-page":"9896","DOI":"10.1182\/blood-2022-162365","volume":"140","author":"E Bryer","year":"2022","unstructured":"Bryer, E. et al. Booster and Btki interruption improve response to Sars-Cov-2 vaccine in patients with CLL. Blood 140 (Supplement 1), 9896\u20139897 (2022).","journal-title":"Blood"},{"issue":"9","key":"18450_CR29","doi-asserted-by":"publisher","first-page":"e077946","DOI":"10.1136\/bmjopen-2023-077946","volume":"13","author":"VS Barber","year":"2023","unstructured":"Barber, V. S. et al. Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia. BMJ Open. 13 (9), e077946 (2023).","journal-title":"BMJ Open."},{"issue":"1","key":"18450_CR30","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/ijms21010068","volume":"21","author":"M Mhibik","year":"2020","unstructured":"Mhibik, M., Wiestner, A. & Sun, C. Harnessing the effects of BTKi on T cells for effective immunotherapy against CLL. Int. J. Mol. Sci. 21 (1), 68 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"18450_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1515\/fco-2015-0026","volume":"8","author":"R Sklavenitis-Pistofidis","year":"2017","unstructured":"Sklavenitis-Pistofidis, R. et al. Targeting Bruton tyrosine kinase: A novel strategy in the treatment of B-cell lymphomas. Forum Clin. Oncol. 8 (1), 7\u201314 (2017).","journal-title":"Forum Clin. Oncol."},{"key":"18450_CR32","doi-asserted-by":"publisher","first-page":"1201415","DOI":"10.3389\/fimmu.2023.1201415","volume":"14","author":"L Li","year":"2023","unstructured":"Li, L. et al. Ibrutinib directly reduces CD8\u2009+\u2009T cell exhaustion independent of BTK. Front. Immunol. 14, 1201415 (2023).","journal-title":"Front. Immunol."},{"issue":"3","key":"18450_CR33","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1158\/1078-0432.CCR-11-2630","volume":"18","author":"C Nunes","year":"2012","unstructured":"Nunes, C. et al. Expansion of a CD8\u2009+\u2009PD-1\u2009+\u2009Replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin. Cancer Res. 18 (3), 678\u2013687 (2012).","journal-title":"Clin. Cancer Res."},{"key":"18450_CR34","doi-asserted-by":"publisher","first-page":"962552","DOI":"10.3389\/fimmu.2022.962552","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Song, Y. & Yin, Q. Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia. Front. Immunol. 13, 962552 (2022).","journal-title":"Front. Immunol."},{"issue":"4","key":"18450_CR35","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1182\/bloodadvances.2021006633","volume":"6","author":"ZL Lyski","year":"2022","unstructured":"Lyski, Z. L. et al. Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia. Blood Adv. 6 (4), 1207\u20131211 (2022).","journal-title":"Blood Adv."},{"issue":"1","key":"18450_CR36","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s12967-021-03136-2","volume":"19","author":"JE Davis","year":"2021","unstructured":"Davis, J. E. et al. Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence. J. Transl Med. 19 (1), 473 (2021).","journal-title":"J. Transl Med."},{"issue":"4","key":"18450_CR37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/PPO.0000000000000059","volume":"20","author":"VA Boussiotis","year":"2014","unstructured":"Boussiotis, V. A., Chatterjee, P. & Li, L. Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J. 20 (4), 265\u2013271 (2014).","journal-title":"Cancer J."},{"issue":"8","key":"18450_CR38","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1074\/jbc.RA119.011150","volume":"295","author":"JE Park","year":"2020","unstructured":"Park, J. E. et al. Leukocyte-associated immunoglobulin-like receptor 1 inhibits T-cell signaling by decreasing protein phosphorylation in the T-cell signaling pathway. J. Biol. Chem. 295 (8), 2239\u20132247 (2020).","journal-title":"J. Biol. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18450-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18450-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18450-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T05:13:44Z","timestamp":1759641224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18450-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,5]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["18450"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-18450-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,5]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34641"}}